After Eli Lilly's stock price surged nearly 300% in four years, Wall Street remains bullish: the "hidden pipeline" beyond GLP-1 is undervalued.
Since the approval of its first GLP-1 drug four years ago, Eli Lilly's stock price has surged nearly 300%, pushing its market capitalization above $1 trillion and making it one of the world's most valuable pharmaceutical companies. Even now, despite the significant price increase, some Wall